trial

Biomarkers in Schizophrenia

NCTId NCT00817336
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 16 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2009-06
Primary completion
2011-07
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
D Serine

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

1 total
Orangeburg, United States

Linked catalysts

1
Biomarkers in Schizophrenia — primary completion2011-07

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE2
Primary Completion Date
2011-07
Status
COMPLETED
relationships
The graph out of here
drug
D Serine
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Daniel C. Javitt, MD, PhD
person